Do sedentary people or athletes have lower glucose levels? Athletes.

Why is the above true? Because exercise sensitizes the cells in the body to the effects

of insulin, thus the body needs less insulin to accomplish the same effect. Also, there is

a more efficient use of glucose in individuals who exercise because of higher

metabolism and increased muscle mass, which decreases the levels of free flowing

glucose intravascularly which in turn reduces the requirements for insulin.

Are people who exercise biologically younger or older? The answer is younger

obviously, that’s why exercise has always been considered a natural form of anti-aging

therapy.

So, using general physiological principals, we have established that lower levels of

insulin exist in athletes. We also know that the more athletic some one is, the younger

the patient is biologically speaking. In other words, a 80-year-old who exercises is

biologically younger than a 80-year-old who rocks in a rocking chair all day.

What is IGF-1? IGF-1 is one of many growth factors. It stands for Insulin Like Growth

Factor, Type 1. There is a reason IGF-1 is called “Insulin Like”. The poly-peptide

sequence of IGF-1 is very similar to that of Insulin. The molecules are very similar in

structure. They also seem to share many of the same properties.

Exercise decreases insulin levels. This is commonly known and understood. Exercise

also decreases IGF-1 levels in athletes. This was clearly established in the initial study

and clinically correlates with the findings of hundreds of clinicians worldwide.

IGF-1 levels may increase with GH injection treatments but remember this is synthetic

GH (recombinant human growth hormone). There is nothing physiological taking place

with the use of synthetic GH. If you inject a synthetic substance into the body and

note a specific change (like IGF-1 levels going up), that DOES NOT mean that the

change noted (IGF-1 going up) is the body’s natural response.

The IGF-1 issue is controversial but remember, IGF-1 may actually be more efficiently

utilized and thus, the levels drop. Or perhaps, the IGF-1 receptor sites are up regulated,

creating a higher binding of IGF-1 so that free serum levels of IGF-1 drop. In this case,

the better level to measure would be IGF-Binding Protein 3 (IGF-BP3). Regardless, it

has clearly been shown that IGF-1 has an association with cancer and is at the very

least, an unreliable indicator of hGH treatment efficacy, if not inversely related. The

extensive references for these statements are available on the website and on the slide

presentation.

with respect to

Overdosage, Neurotoxicity, and possible effects on existing and undiagnosed

Cancers?

Dr. Peter Lim

A:

1. Over dosage: None! Self limiting. Too much Trans-D Tropin® = Too much GHRH

= Too much hGH = Increase in Somatomedian C = decrease in hGH. Thus, the

negative inhibitory feed back loops are initiated in the case of over dosage and

the system shuts off.

2. Neurotoxicity: None!

3. Possible effects on existing cancers: Contraindicated by Balance Dermaceuticals® as a company on a formal basis. However, many doctors have been using it as part of their cancer protocol with superb results. Trans-D Tropin® helps especially with insomnia and anorexia. Patients loose peripheral body fat but increase in lean body mass. Immune levels appear to improve, evidenced clinically by decrease in frequency of URI’s, pneumonia, and influenza syndromes in immuno compromised patients. A new clinical trial measuring CD3/CD4/CD19/CD56 cell activity will soon be underway in the not too distant future.

4. Possible effects on undiagnosed cancers (due to its GH releasing properties).

This is a very controversial topic. Obviously enodgenous hGH is different from

synthetic, recombinant hGH. Can synthetic, recombinant hGH cause cancer? We

don’t know. The literature does indicate it as a possibility. But this is not a

question that is relevant to the subject of Trans-D Tropin®. As far as endogenous

hGH, it definitely has NO relationship to cancer. If it did, then every human being

would have cancer at age 16 to 22 since the endogenous hGH levels are at the

highest levels during late adolescence. And we know that cancer in this age

group is very rare.

As far as the studies on GHRH and it’s association with small cell carcinoma of the lung

are concerned, the study has to be fully read and understood. NO STUDY has ever

been shown that GHRH stimulates the proliferation of cancer cells. To say that

GHRH causes cancer is analogous to saying, “every time there is a fire, we see fire

trucks. We therefore conclude that fire trucks cause fires.” Kiaris, et al showed GHRH

antagonists as a possible new treatment option for small cell lung carcinoma, which is

NOT the same as showing GHRH stimulating proliferation of cancer cells. The question

is by what mechanism do the GHRH antagonists fight these cancers?

Kiaris, et al explain that the GHRH antagonists (inhibitors) shown to suppress the

growth of various cancers, including small cell carcinoma of the lung, are thought to

work by REDUCING the levels of insulin-like growth factors (IGF’s) which are

known as “cancer-causing agents secreted by the liver and by tumors

themselves”. Trans -D Tropin® also DECREASES IGF levels. This has already

been proven in two separate studies on Trans -D Tropin®.

Thus, according to Kiaris et al, a reduction in IGF is responsible for the decrease in

cancer cell proliferation, resulting in positive changes seen in cancer patients. And

since December of 1998, Trans-D Tropin® has been conclusively shown to

decrease IGF levels on a consistent basis. Kiaris et al published their study one full

year later in December of 1999.

Suffice it to say that I treat cancer and heart disease patients that have failed

conventional and sometimes alternative therapies. We have patients from all over the

world with CA. I use Trans-D Tropin® not only in these patients but in my regular patient

population, as well as my own family and myself. I have been on Trans-D Tropin® for

over 18 months. My practice is based on prevention.....you could say that it’s my

business. And Trans-D Tropin® is a major part of it.

Q: If Trans-D Tropin® is all natural, why does it have an NDC number?

Dr. Peter Lim

A: This is a confusing question but an attempt will be made to answer it as best as

possible. Vitaline’s Co-Q 10 studied at Harvard has an NDC number. Yet, Co-Q 10 is all

natural. NDC numbers indicate a product is registered by the FDA and is manufactured

by an FDA approved and registered manufacturing facility. It indicates that the product’s

ingredients are safe and approved for human use. NDC numbers have nothing to do

with being “natural” or not. Usually only pharmaceutical companies make the grade to

have NDC numbers issued for their products. V-SAB Medical Labs, Inc. has met and

exceeded the FDA’s requirements and is registered as a drug manufacturer. Also,

remember, Trans-D Tropin® is only available by prescription which necessitates an NDC

number (in the USA). However, NDC numbers have nothing to do with products being

natural or not.

Q: What tests should a doctor order before starting a patient on Trans-D Tropin®.

Also, if it is all natural, how can we be assured that it will not end up in the health

food stores or over the counter?

Dr. Robert Byrne

The minimum laboratory evaluation prior to starting a patient on Trans-D Tropin® should

be a prolactin or IGF-1 level to rule out a pituitary adenoma or pituitary dysfunction. If

the prescribing physician does not do the appropriate or indicated lab evaluation, then it

is the physician’s own liability that is at risk. The manufacturer, the marketing company

and the distribution companies have no desire to incur the liability of giving Trans-D

Tropin® to a pituitary adenoma patient and risk stimulating the growth of the pituitary

tumor.

The second portion of your question has probably already been answered by the above

answer as well. Although completely safe, in the wrong patient, Trans-D Tropin® is

contraindicated and can have a very detrimental outcome. To adequately control the

usage of this highly efficacious product, it is ONLY available through a pharmacy by

prescription or by a physician with prescription writing privileges (MD/DO). Upon license verification, any doctor can place an order with any of the numerous pharmacies that carry Trans-D Tropin®. Podiatrists and dentists can also purchase Trans-D Tropin® since they are licensed and have prescription writing privileges.

Q: Accurate dosing of Trans-D Tropin® seems difficult to attain using the fliptop

lid currently utilized. How important is this and can this issue be resolved?

Tom Bader, RPh

A: First, it is important to remember that Trans-D Tropin® is analogous to GHRH (the

messenger) telling the pituitary to release hGH. It is also important to remember that

hGH is released in a pulsatile manner from the pituitary. Very simply, in order to attain

the response desired (increasing endogenous hGH release), a threshold level must be

achieved. The number of drops therefore is not as imperative as is achieving the

threshold necessary to release hGH. However, for those clinicians still concerned

regarding dosing methods, Balance Dermaceuticals® has initiated plans for the precise

dosing of Trans-D Tropin® by including an adjunct syringe and a special cap. Balance

Dermaceuticals® should have these additions implemented soon and hopefully in place before 2001.

All questions have been answered by Rashid A. Buttar, DO, FAAPM, FACAM who is also the Medical Director for The Center for Advanced Medicine and Clinical Research and is the Director of Clinical Research and Development for V-SAB Medical Labs, Inc.